TABLE 1.
Characteristics of four automated anti-HCV antibody assays
| Reagent | Analyzer | Manufacturer | HCV antigen
|
Assay principle | Solid phase | Labeled substance | Sample vol (μl) | Time of reaction (min) | Gray zoneb | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Core | NS3 | NS4 | NS5 | |||||||||
| Elecsys Anti-HCV | Cobas e 411 | Roche Diagnostics | Present | Present | Present | Absent | ECLIAa | Magnetic particle | Ruthenium complex | 40 | 18 | 0.9-1.0 |
| Architect Anti-HCV | Architect i2000 | Abbott Laboratories | Present (HCr43) | Present (HCr43) | Present (c100-3) | Absent | CLIA | Paramagnetic particle | Acridinium | 20 | 29 | Not indicated |
| Vitros Anti-HCV | Vitros ECiQ | Ortho-Clinical Diagnostics | Present (c22-3) | Present (c200) | Present (c200) | Present | CLIA | Well | Luminol derivative | 20 | 56 | 0.9-1.0 |
| Access HCV Ab PLUS | UniCel DxI 800 | Bio-Rad Laboratories/Beckman-Coulter | Present | Present | Present | Absent | CLIA | Paramagnetic particle | Lumi-Phos 530 | 25 | 55 | 0.9-1.0 |
a
ECLIA, electrochemiluminescence immunoassay.
b
Shown is the s/co ratio of the gray zone requiring retest according to the manufacturer.